MERCURIUS™ FLASH-seq is based on the method first published in Nature Biotechnology. Alithea Genomics significantly enhanced the original FLASH-seq method to offer a streamlined workflow and superior data output. The plate-based kit (available in 96- and 384-well formats) features a novel, non-toxic tagmentation buffer and delivers ultra-sensitive gene detection, capturing up to two times more genes compared to other commercially available solutions.
MERCURIUS™ FLASH-seq provides full-length transcript coverage, empowering researchers to explore differential gene expression, detect alternative splicing, and analyze isoform diversity—all critical for understanding complex biology, especially in rare cell populations.
“With MERCURIUS™ FLASH-seq, we are removing long-standing barriers in single cell RNA-seq to make full-length, high-resolution transcriptomics truly accessible,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “Researchers studying rare cells or running high-throughput screens no longer have to compromise between sensitivity, scale, and cost. This launch is a bold step toward accelerating drug discovery and deepening our understanding of disease biology.”
Alithea is now accepting orders for MERCURIUS™ FLASH-seq kits and services.
Attendees of the Festival of Genomics and Biodata Boston (June 2025) are invited to visit Alithea Genomics at booth 67B to learn more about MERCURIUS™ FLASH-seq and speak with the team behind the technology.
About RNA Sequencing
RNA sequencing (RNA-seq) examines the quantity and sequences of RNA molecules in a biological sample using next-generation sequencing (NGS). By revealing which genes are expressed and to what extent, RNA-seq provides a high-resolution view of cellular function. These insights are essential across the drug discovery pipeline, from biomarker discovery to therapeutic development.
About Alithea Genomics
Alithea Genomics develops innovative, massively multiplexed RNA-seq solutions designed to accelerate high-throughput transcriptomics. Its proprietary MERCURIUS™ DRUG-seq and MERCURIUS™ BRB-seq technologies dramatically reduce the cost and complexity of generating large-scale RNA data, unlocking the potential of AI and machine learning and enabling breakthroughs in drug development, crop engineering, cosmetics, and beyond. Founded in 2020 at EPFL in Lausanne, Switzerland, Alithea Genomics operates in Europe and the United States.